Company intelligence
Persevere Therapeutics
We are an oncology company advancing a novel antineoplastic therapeutic for patients with difficult-to-treat cancers.
About Persevere Therapeutics
Persevere Therapeutics is a clinical-stage oncology company dedicated to advancing a novel antineoplastic therapeutic for patients with difficult-to-treat cancers. The name Persevere reflects an enduring reminder that we must ‘never give up’ on behalf of cancer patients who persevere every day. Our mission is the singular pursuit of improved clinical outcomes for cancer patients with our novel therapeutic, misetionamide (GP-2250). Our lead clinical focus is the treatment of platinum-resistant ovarian cancer. Misetionamide is a broadly active small molecule with a novel mechanism of action that inhibits two oncogenic transcription factors, c-MYC and NFκB. Through modulation of c-MYC, misetionamide selectively disrupts cancer cell energy metabolism, leading to tumor cell death. In parallel, inhibition of NFκB reduces cancer cell proliferation and survival signaling.
Verified activity
Signals from Persevere Therapeutics
2 published signals